Abstract:CDKL5 deficiency disorder (CDD) is a genetic disease that produces lifelong neurological dysfunction, including autism, intellectual disability and epilepsy. This study employed a clinically relevant mouse model of CDD to investigate the effects of cannabidiol (CBD) on behavioural outcomes and found that it attenuates seizure susceptibility, memory impairments and social behavioural deficits. The clinical impact of this research is potentially very high, as CBD is already FDA‐approved for epilepsy. The study also demonstrates altered signalling related to the endogenous endocannabinoid system in CDD, which could inform the development of novel therapies with more specific endocannabinoid receptor modulators. Cyclin‐dependent kinase‐like 5 (CDKL5) deficiency disorder (CDD) is caused by a loss‐of‐function mutation in CDKL5 gene, encoding a serine–threonine kinase highly expressed in the brain. CDD manifests with early‐onset epilepsy, autism, motor impairment and severe intellectual disability. While there are no known treatments for CDD, the use of cannabidiol has recently been introduced into clinical practice for neurodevelopmental disorders. Given the increased clinical utilization of cannabidiol, we examined its efficacy in the CDKL5R59X knock‐in (R59X) mice, a CDD model based on a human mutation that exhibits both lifelong seizure susceptibility and behavioural deficits. We found that cannabidiol pre‐treatment rescued the increased seizure susceptibility in response to the chemoconvulsant pentylenetetrazol (PTZ), attenuated working memory and long‐term memory impairments, and rescued social deficits in adult R59X mice. To elucidate a potential mechanism, we compared the developmental hippocampal and cortical expression of common endocannabinoid (eCB) targets in R59X mice and their wild‐type littermates, including cannabinoid type 1 receptor (CB1R), transient receptor potential vanilloid type 1 (TRPV1) and 2 (TRPV2), G‐coupled protein receptor 55 (GPR55) and adenosine receptor 1 (A1R). Many of these eCB targets were developmentally regulated in both R59X and wild‐type mice. In addition, adult R59X mice demonstrated significantly decreased expression of CB1R and TRPV1 in the hippocampus, and TRPV2 in the cortex, while TRPV1 was increased in the cortex. These findings support the potential for dysregulation of eCB signalling as a plausible mechanism and therapeutic target in CDD, given the efficacy of cannabidiol to attenuate hyperexcitability and behavioural deficits in this disorder.

Cannabidiol Ameliorates Cognitive Decline in 5×FAD Mouse Model of Alzheimer’s Disease Through Potentiating the Function of Extrasynaptic Glycine Receptors

Cannabidiol ameliorates cognitive decline in 5×FAD mouse model of Alzheimer's disease through potentiating the function of extrasynaptic glycine receptors

Cannabidiol Ameliorates Cognitive Decline in 5xfad Mouse Model of Alzheimer's Disease Through Potentiating the Function of Extrasynaptic Glycine Receptors

Cannabidiol improves the cognitive function of SAMP8 AD model mice involving the microbiota-gut-brain axis

Boosting Acetylcholine Signaling by Cannabidiol in a Murine Model of Alzheimer's Disease

A butyrolactone derivative 3BDO alleviates memory deficits and reduces amyloid-β deposition in an AβPP/PS1 transgenic mouse model.

A combination of Δ9-tetrahydrocannabinol and cannabidiol modulates glutamate dynamics in the hippocampus of an animal model of Alzheimer's disease

Cannabidiol protects mouse hippocampal neurons from neurotoxicity induced by amyloid β-peptide 25–35

Cannabidiol protects against Alzheimer's disease in C. elegans via ROS scavenging activity of its phenolic hydroxyl groups

A Comprehensive Exploration of the Multifaceted Neuroprotective Role of Cannabinoids in Alzheimer's Disease across a Decade of Research

Synergetic effect of β-asarone and cannabidiol against Aβ aggregation in vitro and in vivo

Activation of CB2 Receptor System Restores Cognitive Capacity and Hippocampal Sox2 Expression in a Transgenic Mouse Model of Alzheimer's Disease

Exploring Cannabinoids with Enhanced Binding Affinity for Targeting the Expanded Endocannabinoid System: A Promising Therapeutic Strategy for Alzheimer's Disease Treatment

FAAH Inhibition as a Path to Mitigate Alzheimer's Disease Progression in Mouse Models of Amyloidosis

Diethyl butylmalonate attenuates cognitive deficits and depression in 5×FAD mice

Alzheimer's disease, aging, and cannabidiol treatment: a promising path to promote brain health and delay aging

Cannabidiol in the treatment and prevention of Alzheimer’s disease – a comprehensive overview of in vitro and in vivo studies

Cannabidivarin alleviates α-synuclein aggregation via DAF-16 in Caenorhabditis elegans

Dendrobine Ameliorates Alzheimer's Disease-like Pathology and Cognitive Decline in 3 × Tg-AD Mice

Cannabidiol attenuates seizure susceptibility and behavioural deficits in adult CDKL5R59X knock‐in mice

Reversible GABAergic dysfunction involved in hippocampal hyperactivity predicts early-stage Alzheimer disease in a mouse model